Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Net Income (2016 - 2025)

Historic Net Income for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to -$544000.0.

  • Zevra Therapeutics' Net Income rose 9836.27% to -$544000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $35.3 million, marking a year-over-year increase of 13939.71%. This contributed to the annual value of -$105.5 million for FY2024, which is 12912.77% down from last year.
  • As of Q3 2025, Zevra Therapeutics' Net Income stood at -$544000.0, which was up 9836.27% from $74.7 million recorded in Q2 2025.
  • In the past 5 years, Zevra Therapeutics' Net Income ranged from a high of $74.7 million in Q2 2025 and a low of -$35.7 million during Q4 2024
  • Its 5-year average for Net Income is -$5.6 million, with a median of -$10.3 million in 2021.
  • As far as peak fluctuations go, Zevra Therapeutics' Net Income skyrocketed by 62211.87% in 2021, and later crashed by 67438.79% in 2024.
  • Over the past 5 years, Zevra Therapeutics' Net Income (Quarter) stood at -$2.7 million in 2021, then surged by 368.41% to $7.3 million in 2022, then crashed by 374.18% to -$19.9 million in 2023, then crashed by 79.67% to -$35.7 million in 2024, then skyrocketed by 98.48% to -$544000.0 in 2025.
  • Its Net Income stands at -$544000.0 for Q3 2025, versus $74.7 million for Q2 2025 and -$3.1 million for Q1 2025.